Compare Stocks: VOR, ABCL, RLAY, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$13.78 +0.3%	$10.65	$2.74 ▼ $15.02	$4.23B	1.41	6.10 million shs	4.07 million shs
RLAY Relay Therapeutics	$19.39 +2.3%	$19.11	$5.47 ▼ $21.27	$4.25B	1.72	3.20 million shs	2.94 million shs
TNGX Tango Therapeutics	$23.08 -0.7%	$24.85	$6.69 ▼ $34.39	$3.89B	1.17	3.38 million shs	1.94 million shs
VOR Vor Biopharma	$18.58 -0.6%	$22.09	$6.50 ▼ $38.31	$1.10B	1.78	1.07 million shs	648,498 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+8.19%	+20.21%	+74.59%	+132.88%
RLAY Relay Therapeutics	0.00%	+8.53%	-0.42%	+0.32%	+245.99%
TNGX Tango Therapeutics	0.00%	-6.74%	+3.20%	-22.38%	+199.48%
VOR Vor Biopharma	0.00%	+0.92%	-25.39%	-7.01%	-50.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$13.78 +0.3%	$10.65	$2.74 ▼ $15.02	$4.23B	1.41	6.10 million shs	4.07 million shs
RLAY Relay Therapeutics	$19.39 +2.3%	$19.11	$5.47 ▼ $21.27	$4.25B	1.72	3.20 million shs	2.94 million shs
TNGX Tango Therapeutics	$23.08 -0.7%	$24.85	$6.69 ▼ $34.39	$3.89B	1.17	3.38 million shs	1.94 million shs
VOR Vor Biopharma	$18.58 -0.6%	$22.09	$6.50 ▼ $38.31	$1.10B	1.78	1.07 million shs	648,498 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+8.19%	+20.21%	+74.59%	+132.88%
RLAY Relay Therapeutics	0.00%	+8.53%	-0.42%	+0.32%	+245.99%
TNGX Tango Therapeutics	0.00%	-6.74%	+3.20%	-22.38%	+199.48%
VOR Vor Biopharma	0.00%	+0.92%	-25.39%	-7.01%	-50.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$13.38	-2.94% Downside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	33.66% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	88.31% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$41.71	124.51% Upside

Current Analyst Ratings Breakdown

Latest VOR, ABCL, RLAY, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	RLAY Relay Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/29/2026	ABCL AbCellera Biologics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
9/24/2026	ABCL AbCellera Biologics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00
9/14/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/14/2026	RLAY Relay Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $31.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	56.24	N/A	N/A	$3.23 per share	4.27
RLAY Relay Therapeutics	$15.35M	276.82	N/A	N/A	$3.27 per share	5.93
TNGX Tango Therapeutics	$62.38M	62.38	N/A	N/A	$2.57 per share	8.98
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/9/2026 (Confirmed)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, ABCL, RLAY, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
RLAY Relay Therapeutics	N/A	18.27	18.27
TNGX Tango Therapeutics	N/A	50.82	50.82
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
RLAY Relay Therapeutics	96.98%
TNGX Tango Therapeutics	78.99%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
RLAY Relay Therapeutics	5.04%
TNGX Tango Therapeutics	6.50%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	N/A

VOR, ABCL, RLAY, and TNGX Headlines

Recent News About These Companies

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 minutes ago | globenewswire.com

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

October 4 at 2:16 PM | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

September 30, 2026 | marketbeat.com

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | finanznachrichten.de

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | marketscreener.comM

Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes

September 29, 2026 | boursorama.comB

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | globenewswire.com

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

September 29, 2026 | theglobeandmail.com

Vor Biopharma Inc. (NASDAQ:VOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

September 28, 2026 | americanbankingnews.com

Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages

September 28, 2026 | marketbeat.com

【VOR】Vor Biopharma

September 23, 2026 | note.comN

Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia

September 23, 2026 | br.investing.com

Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局

September 23, 2026 | cn.investing.com

Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia

September 23, 2026 | it.investing.com

Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía

September 23, 2026 | mx.investing.com

Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?

September 22, 2026 | marketbeat.com

Vor Biopharma: A Funded Replication Story With Franchise Potential

September 18, 2026 | seekingalpha.com

Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VOR, ABCL, RLAY, and TNGX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$13.78 +0.04 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$13.78 0.00 (0.00%)

As of 06:05 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Relay Therapeutics NASDAQ:RLAY

$19.39 +0.43 (+2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$19.32 -0.07 (-0.35%)

As of 06:03 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$23.08 -0.16 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$23.06 -0.02 (-0.11%)

As of 04:46 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Vor Biopharma NASDAQ:VOR

$18.58 -0.11 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$18.82 +0.25 (+1.32%)

As of 04:43 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VOR, ABCL, RLAY, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VOR, ABCL, RLAY, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VOR, ABCL, RLAY, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VOR, ABCL, RLAY, and TNGX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Relay Therapeutics NASDAQ:RLAY

Tango Therapeutics NASDAQ:TNGX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VOR, ABCL, RLAY, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VOR, ABCL, RLAY, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VOR, ABCL, RLAY, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VOR, ABCL, RLAY, and TNGX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Relay Therapeutics NASDAQ:RLAY

Tango Therapeutics NASDAQ:TNGX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools